Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
about
A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frameHerpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compoundsBiochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activityRapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementHerpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapyAntiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus.Mechanism of copper-mediated inactivation of herpes simplex virus.Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1Resistance of herpesviruses to antiviral drugsNucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.Mucocutaneous infections with herpes simplex virus and their management.Antiviral therapy: current concepts and practicesOral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.Persistent herpes simplex virus infection and mechanisms of virus drug resistance.Survey of resistance of herpes simplex virus to acyclovir in northwest England.Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet.Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir.In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment."The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.Analysis of the relationship between cellular thymidine kinase activity and virulence of thymidine kinase-negative herpes simplex virus types 1 and 2.Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
P2860
Q28344045-8A1188E7-4675-4B60-A5DD-E1901CBD93EFQ28361992-F8EAED57-934D-4885-A908-99C62E8107F0Q28367467-CF54E656-06B9-4477-AD7A-B6F5E2FBA7B0Q28378750-F28040DD-24CF-4BE2-874A-463CFC05120BQ33966906-B4A4902F-F157-49DE-BB27-501D73BC7893Q33980379-DFD5E2EE-7DAD-4536-AAAF-FC7B9D5367A3Q33980794-3F3896F7-61B6-42EF-B5E9-1F823589089AQ34149904-66141717-814C-44EE-BBC7-081280389678Q34579981-48C412D6-F5AC-4F3D-BEE8-617ACD2550E8Q35115200-9459BE26-B578-4D42-86C4-A852D253E9A5Q35135080-AA6BC580-B609-4EAC-A63A-4159D12604ECQ35244752-B4DC2208-58F7-447D-890D-63A874BC3EE3Q35447500-78ACA005-2D10-406D-B0A5-D9A36FD3272BQ35542181-23599C55-793A-4473-8D23-A3C556AC4286Q35545099-11FF5396-3E96-440F-A1E1-10DB8964B155Q36070394-0DCFFC61-2484-49DC-A1DB-C9BE929767C5Q36478736-D337AA49-2171-457F-B3D7-49D1228677C4Q38287183-6D04074E-F60A-4231-B270-090465746824Q39557442-B6450DA4-2DA4-4965-A404-023A4EC783B1Q39785429-5BA744A2-ED41-42DD-A789-57BC27386279Q39879440-F25E5128-4F2B-44A4-9831-D2D4EF275C08Q40088021-83F3A5BE-8DB3-4655-84A1-7AD3C54ECCA2Q40115283-00BB0269-2844-4F26-999C-DC1F7A5561CAQ40720231-63BC2D51-9C9F-4186-9C47-E8103CC45C83Q40782481-141C5766-3808-4814-A9B2-7A86F91939F6Q41386818-D0CF464B-14BA-4BB7-9B6B-AE912EE6883BQ44354849-E6D9981C-BD3F-4565-9BA4-496A26C381C9Q45777522-9F95FE10-3D5E-4856-B284-A6E35E65EB57
P2860
Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
description
1987 nî lūn-bûn
@nan
1987 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Clinical isolate of herpes sim ...... altered substrate specificity.
@ast
Clinical isolate of herpes sim ...... altered substrate specificity.
@en
type
label
Clinical isolate of herpes sim ...... altered substrate specificity.
@ast
Clinical isolate of herpes sim ...... altered substrate specificity.
@en
prefLabel
Clinical isolate of herpes sim ...... altered substrate specificity.
@ast
Clinical isolate of herpes sim ...... altered substrate specificity.
@en
P2093
P2860
P356
P1476
Clinical isolate of herpes sim ...... altered substrate specificity.
@en
P2093
Lehrman SN
P2860
P304
P356
10.1128/AAC.31.7.1117
P407
P577
1987-07-01T00:00:00Z